CN121202809A - {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 - Google Patents

{2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途

Info

Publication number
CN121202809A
CN121202809A CN202511373032.0A CN202511373032A CN121202809A CN 121202809 A CN121202809 A CN 121202809A CN 202511373032 A CN202511373032 A CN 202511373032A CN 121202809 A CN121202809 A CN 121202809A
Authority
CN
China
Prior art keywords
crystalline form
formula
degrees
peaks
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511373032.0A
Other languages
English (en)
Chinese (zh)
Inventor
滕菁
曹亦铮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
vTv Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by vTv Therapeutics LLC filed Critical vTv Therapeutics LLC
Publication of CN121202809A publication Critical patent/CN121202809A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN202511373032.0A 2020-06-08 2021-06-07 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 Pending CN121202809A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063035994P 2020-06-08 2020-06-08
US63/035,994 2020-06-08
CN202180056233.1A CN116056760A (zh) 2020-06-08 2021-06-07 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途
PCT/US2021/036082 WO2021252309A1 (en) 2020-06-08 2021-06-07 Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180056233.1A Division CN116056760A (zh) 2020-06-08 2021-06-07 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途

Publications (1)

Publication Number Publication Date
CN121202809A true CN121202809A (zh) 2025-12-26

Family

ID=78846441

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202511373032.0A Pending CN121202809A (zh) 2020-06-08 2021-06-07 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途
CN202180056233.1A Pending CN116056760A (zh) 2020-06-08 2021-06-07 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180056233.1A Pending CN116056760A (zh) 2020-06-08 2021-06-07 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途

Country Status (9)

Country Link
US (1) US20230219910A1 (https=)
EP (1) EP4161639A4 (https=)
JP (1) JP2023530785A (https=)
KR (1) KR20230048501A (https=)
CN (2) CN121202809A (https=)
AU (1) AU2021289591A1 (https=)
CA (1) CA3181665A1 (https=)
MX (2) MX2022015524A (https=)
WO (1) WO2021252309A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1213197A1 (zh) * 2013-03-04 2016-06-30 Vtv治疗有限责任公司 包括葡糖激酶活化劑的固體組合物及其製備和使用方法
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CA3181722A1 (en) 2020-06-08 2021-12-16 Jing TENG Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0506662B8 (pt) * 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
NZ603614A (en) * 2010-05-26 2014-10-31 Transtech Pharma Llc Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
BR112014028622A2 (pt) * 2012-05-17 2017-06-27 Transtech Pharma Llc composições de ativador de glucoquinase para o tratamento de diabetes
HK1213197A1 (zh) * 2013-03-04 2016-06-30 Vtv治疗有限责任公司 包括葡糖激酶活化劑的固體組合物及其製備和使用方法
CN105050585A (zh) * 2013-03-04 2015-11-11 Vtv治疗有限责任公司 稳定的葡萄糖激酶活化剂组合物
EP3556354B1 (en) * 2016-12-15 2025-05-21 Hua Medicine (Shanghai) Ltd. Oral preparation of glucokinase activator and preparation method therefor

Also Published As

Publication number Publication date
MX2022015524A (es) 2023-03-22
JP2023530785A (ja) 2023-07-19
US20230219910A1 (en) 2023-07-13
KR20230048501A (ko) 2023-04-11
CA3181665A1 (en) 2021-12-16
EP4161639A4 (en) 2024-01-17
AU2021289591A1 (en) 2023-01-19
EP4161639A1 (en) 2023-04-12
WO2021252309A1 (en) 2021-12-16
MX2026000786A (es) 2026-03-02
CN116056760A (zh) 2023-05-02

Similar Documents

Publication Publication Date Title
CN121202809A (zh) {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途
EP2989084B1 (en) Crystal modifications of elobixibat
CN110922407B (zh) 苯甲酰氨基吡啶衍生物的晶型及其用途
CN112638904A (zh) 2-(3,5-二氯-4-((5-异丙基-6-氧代-1,6-二氢哒嗪-3-基)氧基)苯基)-3,5-二氧代-2,3,4,5-四氢-1,2,4-三嗪-6-腈的固体形式
EP4010322B1 (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
CN116194442A (zh) {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的盐或共晶体及其用途
TW202333676A (zh) 吡唑並〔３，４－ｄ〕嘧啶化合物之固體形式
CN118894894A (zh) 新生霉素类似物与脯氨酸的共晶体形式
US12030886B2 (en) Form of ponatinib
CN102770416B (zh) 美他沙酮共晶体
US20220251091A1 (en) Amorphous umbralisib monotosylate
KR20220012222A (ko) 방향족 화합물의 고체 형태 및 그 제조 방법
HK40119275A (zh) 新生霉素类似物与脯氨酸的共晶体形式
US20210032235A1 (en) Crystalline forms of dasatinib
US20220298158A1 (en) Polymorph of venetoclax and method for preparing the polymorph
HK40112450A (zh) 吡唑并[3，4-d]嘧啶化合物的固体形式
HK40074778A (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
HK40074778B (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
CA3057716A1 (en) Novel forms of afatinib dimaleate
HK1221224B (en) Crystal modifications of elobixibat

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination